China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.
China SXT Pharmaceuticals Stock Down 3.8%
SXTC traded down $0.06 during midday trading on Friday, hitting $1.52. The company's stock had a trading volume of 41,040 shares, compared to its average volume of 1,930,118. The company has a quick ratio of 3.40, a current ratio of 3.54 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $1.70 and a two-hundred day moving average price of $2.40. China SXT Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $8.64.
About China SXT Pharmaceuticals
(
Get Free Report)
China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Featured Articles
Before you consider China SXT Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.
While China SXT Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access